Peter McGrail
Analyst · Raymond James. Your line is now open
Thanks, Steve. Let me walk through the results in more detail. Total revenue for the quarter was $55.2 million, which represents a 60.8% increase from the year-ago quarter. Our total recurring revenue of $52.3 million was up 61.3% from the year-ago quarter and represented 95% of our total revenue. As Steve mentioned, this tremendous growth was attributable to the wide acceptance by our clients of our ACA Enhanced solution as well as the performance of our sales team. The second quarter also benefited from a favorable calendar, as we experienced very high levels of payroll activity related to yearend bonuses and adjustment runs. Recurring fees were up 61.4% in the quarter and interest revenue increased 57.7% year-over-year, primarily as a result of our client growth and balance increases. Implementation services and other revenue was $2.8 million for the quarter, up 51.9% from the year-ago quarter. Within our implementation services and other revenue category, payroll start-up revenue was particularly strong. As Steve noted in his remarks, we did have a number of clients start in October and November versus January, so that their 2015 ACA data could be managed in a single platform. We are also pleased to report that our annual revenue retention rate, which is always calculated on a trailing 12-month basis, remained above 92% as it has for several years. As we've noted in the past, we believe this is best-in-class for our segment. The combination of high recurring revenue percentages and high retention rates, provide significant visibility into our future operating results. Adjusted gross profit in the quarter was $33.3 million, representing margin of 60.3%, as compared to $17.8 million or 51.9% in the year-ago quarter, an 840 basis point improvement. ACA Enhanced, a higher margin to product, was a key driver to this increase along with improvements related to our second reseller acquisition, strong performance by our sales team and other natural cost leverage. We view our adjusted recurring revenue gross margins as the best indicator of our overall long-term margin opportunity as we generate these margins on greater than 95% of our revenues. Our adjusted gross profit on recurring revenues was $38.1 million or 72.8% in the second quarter, up from $21.6 million or 66.7% in the year-ago quarter, a 610 basis point improvement. Again, this improvement was a combination of the wide adoption of our ACA Enhanced product along with improvements attributable to our second reseller acquisition and other natural cost leverage. Given the large-scale adoption of our ACA Enhanced product and the tremendous performance of our sales team, we began adding significant additional operational resources at the tail end of the second quarter and plan to continue this trend over the next few quarters. Amongst other benefits, this will allow us to provide ongoing ACA related support to our clients as well as maintain the highest overall service levels. We continue to invest in research and development. In addition to significant new modules such as ACA, we are equally committed to refreshing and modernizing our platform to maintain and extend our technological advantage. In order to understand our overall investment in research and development, it is important to combine both what we expense and what we capitalize. On a combined non-GAAP basis, total research and development investments were $7.7 million or 14% of revenue in the second quarter, up 51% increase from the year-ago quarter. On a non-GAAP basis, sales and marketing expense was $13.1 million or 23.8% of revenue in the quarter, compared to $8.5 million or 24.7% in the same period last year. We are especially pleased that we were able to achieve significant penetration of our ACA Enhanced product without a significant increase in sales costs. On a non-GAAP basis, general and administrative costs were $8.8 million or 15.9% of revenue in the quarter, compared to $6.6 million or 19.1% of revenue in the year-ago quarter, a 320 basis point improvement. We continue to leverage our G&A costs following our IPO in March of 2014. Our adjusted EBITDA was $7.2 million for the quarter versus a loss of $0.2 million for the year-ago quarter. For the first six months of our fiscal year, we've generated $10.5 million of adjusted EBITDA versus $0.1 million for the same period last year and $8.2 million for all of last fiscal year. Non-GAAP net income was $4.1 million or $0.8 per share for the quarter versus a loss of $2.3 million or negative $0.05 per share in the year-ago quarter. For the first six months of our fiscal year, we've generated $4.9 million of non-GAAP net income versus a loss of $3.7 million for the same period last year and non-GAAP net income of approximately $0.4 million for all of last fiscal year. Briefly covering our GAAP results; for the quarter gross profit was $31.1 million, operating loss was $1.3 million and net loss was $1.2 million. In regard to the balance sheet, we ended the quarter with cash and cash equivalents of $79 million. Cash flows generated by operating activities were $7.8 million in the quarter versus $1 million in the year-ago quarter. This increase was the direct result of our increased on non-GAAP net income in the quarter. For the first six months of our fiscal year, we've generated $10.8 million of operating cash flows versus point $0.8 million for the same period last year and $11.1 million for all of last fiscal year. Finally, I'd like to provide our financial guidance for the third quarter and updated guidance for the full year of fiscal 2016. In the third quarter, total revenue is expected to be in the range of $66.5 million to $67.5 million, which represents 41% to 43% growth over the third quarter of last year. Adjusted EBITDA is expected to be in the range of $10.5 million to $11.5 million. Non-GAAP net income is expected to be in the range of $7 million to $8 million or $0.13 per share to $0.15 per share based on approximately $54 million diluted weighted average common shares outstanding. For the fiscal year, total revenue is expected to be in the range of $223 million to $225 million, an increase of $12 million at the midpoint from our previous guidance and representing 46% to 47% growth over last year. Adjusted EBITDA is expected to be in the range of $22 million to $23 million. Non-GAAP net income is expected to be in the range of $9.5 million to $10.5 million or $0.18 to $0.19 per share based on approximately $54 million diluted weighted average common shares outstanding. In summary, we are very pleased with our performance during the quarter highlighted by wide adoption of our ACA Enhanced product and excellent sales execution. We experienced the greatest quarterly revenue growth on a percentage in dollar basis in our history along with tremendous gross margin expansion and substantial G&A expense leverage. As a result, we are meaningfully raising guidance for the full fiscal year. One final note, Steve will be attending the JMP Technology Conference in San Francisco on February 29, and I will be attending the Northland Growth Conference on March 9 in New York. Operator, we are now ready to begin the Q&A session.